Our Funding
Overview
Our funders
SMA Europe receives funding from its member organisations, in the form of an annual membership fee and of voluntary donations towards our Call for Research Proposals. In addition, we receive funding from other non-profit organisations and from health sector corporates.
Our funders respect SMA Europe’s mission, strategy, independence, and integrity.
SMA Europe has adopted a code of practice for relationships with the pharmaceutical industry and all our funding partnerships are established with shared interest, transparency, trust, and mutual benefit.
For more information, please contact us at secretariat@sma-europe.eu.
Breakdown
Financial information 2020
In 2020 SMA Europe’s annual revenue was of € 833 317,58 while the organisation’s total annual expenses amounted to € 538 884,13.
Revenue received from health sector corporates
In 2020, SMA Europe received funding from 5 health sector corporate donors, amounting to a total of € 292 141,00.
The breakdown of each company’s donations is detailed in the graphic below.
Valued support
Acknowledgements
SMA Europe appreciates the donations received from all its funders. Ensuring a sustained variety of funding is key to minimise potential conflicts of interest and to ensure the sustainability of the organisation.
SMA Europe would like to thank the following organisations for their highly valued support in 2020:
- SMA Europe’s member organisations
- Cure SMA
- Avexis
- Biogen
- Novartis
- Roche
- Wallac Oy
Related resources